Renewal of the GMP Certificate for the mechanical unit of Porto Alegre – RS. The RPHNEFRO (DTPA) is the third Cold Kit to receive its marketing authorization. Beginning of the construction work of the second RPH Pharm unity in the city of Rio de Janeiro – RJ.
Three more Cold Kit registers were achieved: RPH NEFRO, RPH RENO and RPH LIMPHA.

RPHKARDIA (MIBI) is the second Cold Kit to receive its register. High investments allow the expansion of the productive unit of RPH Pharma that has its production capacity increased, allowing the company to expand its international market share.

RPHOSTEO (MDP) is the first Cold Kit to receive its marketing authorisation in the history of Brazilian radiopharmacy. RPH Central Pharma, the first radiopharmacy centralized in Brazil is dedicated in São Paulo.

Portfolio following ANVISA’s regulatory requirements, including Lantheus generator.

Becomes the first certified company in the sector, obtaining the GMP certification for the productive plant.

Conception of the new brand. The company becomes RPH Group. Beginning of ITG (Isotope Technologies Garching) partnership and introduction of the Ga-68 new technology in the Brazilian nuclear medicine market.

The company’s capital has now the investment funds of Criatec (Brazilian investment fund).

Nuclear medicine is improved in Brazil, with the opening of the production unit and the supply of Cold Kits on a national scale. The facilities located in Porto Alegre – RS are modern and present an efficient plan to ensure sustainability to nuclear medicine sector.

Installation in TECNOPUC-RS, one of the biggest development innovation and technology parks in Latin America.

Conception of Radiopharmacus Solutions in Nuclear Medicine specialized in consulting, services, training and qualification in radiopharmacy area.